PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Faure-Dupuy, S.* ; Riedl, T.* ; Rolland, M.* ; Hizir, Z.* ; Reisinger, F. ; Neuhaus, K.* ; Schuehle, S.* ; Remouchamps, C.* ; Gillet, N.* ; Schönung, M.* ; Stadler, M.* ; Wettengel, J.M. ; Barnault, R.* ; Parent, R.* ; Schuster, L.C.* ; Farhat, R.* ; Prokosch, S.* ; Leuchtenberger, C.* ; Öllinger, R.* ; Engleitner, T.* ; Rippe, K.* ; Rad, R.* ; Unger, K. ; Tscharahganeh, D.* ; Lipka, D.B.* ; Protzer, U. ; Durantel, D.* ; Lucifora, J.* ; Dejardin, E.* ; Heikenwälder, M.*

Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p.

JHEP Rep. 3:100354 (2021)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Background & Aims: Immune-mediated induction of cytidine deaminase APOBEC3B (A3B) expression leads to HBV covalently closed circular DNA (cccDNA) decay. Here, we aimed to decipher the signalling pathway(s) and regulatory mechanism(s) involved in A3B induction and related HBV control. Methods: Differentiated HepaRG cells (dHepaRG) knocked-down for NF-κB signalling components, transfected with siRNA or micro RNAs (miRNA), and primary human hepatocytes ± HBV or HBVΔX or HBV-RFP, were treated with lymphotoxin beta receptor (LTβR)-agonist (BS1). The biological outcomes were analysed by reverse transcriptase-qPCR, immunoblotting, luciferase activity, chromatin immune precipitation, electrophoretic mobility-shift assay, targeted-bisulfite-, miRNA-, RNA-, genome-sequencing, and mass-spectrometry. Results: We found that canonical and non-canonical NF-κB signalling pathways are mandatory for A3B induction and anti-HBV effects. The degree of immune-mediated A3B production is independent of A3B promoter demethylation but is controlled post-transcriptionally by the miRNA 138-5p expression (hsa-miR-138-5p), promoting A3B mRNA decay. Hsa-miR-138-5p over-expression reduced A3B levels and its antiviral effects. Of note, established infection inhibited BS1-induced A3B expression through epigenetic modulation of A3B promoter. Twelve days of treatment with a LTβR-specific agonist BS1 is sufficient to reduce the cccDNA pool by 80% without inducing significant damages to a subset of cancer-related host genes. Interestingly, the A3B-mediated effect on HBV is independent of the transcriptional activity of cccDNA as well as on rcDNA synthesis. Conclusions: Altogether, A3B represents the only described enzyme to target both transcriptionally active and inactive cccDNA. Thus, inhibiting hsa-miR-138-5p expression should be considered in the combinatorial design of new therapies against HBV, especially in the context of immune-mediated A3B induction. Lay summary: Immune-mediated induction of cytidine deaminase APOBEC3B is transcriptionally regulated by NF-κB signalling and post-transcriptionally downregulated by hsa-miR-138-5p expression, leading to cccDNA decay. Timely controlled APOBEC3B-mediated cccDNA decay occurs independently of cccDNA transcriptional activity and without damage to a subset of cancer-related genes. Thus, APOBEC3B-mediated cccDNA decay could offer an efficient therapeutic alternative to target hepatitis B virus chronic infection.
Impact Factor
Scopus SNIP
Altmetric
0.000
0.401
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter A20, Tumour Necrosis Factor Alpha-induced Protein 3 ; Apobec3a/a3a, Apolipoprotein B Mrna Editing Catalytic Polypeptide-like A ; Apobec3b ; Apobec3b/a3b, Apolipoprotein B Mrna Editing Catalytic Polypeptide-like B ; Apobec3g/a3g, Apolipoprotein B Mrna Editing Catalytic Polypeptide-like G ; Bca, Bicinchoninic Acid Assay ; Chb, Chronic Hepatitis B ; Cxcl10, C-x-c Motif Chemokine Ligand 10 ; Chip, Chromatin Immune Precipitation ; Emsa, Electrophoretic Mobility-shift Assay ; H3k4me3, Histone 3 Lysine 4 Trimethyl
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2589-5559
e-ISSN 2589-5559
Zeitschrift JHEP Reports
Quellenangaben Band: 3, Heft: 6, Seiten: , Artikelnummer: 100354 Supplement: ,
Verlag Elsevier
Institut(e) Institute of Virology (VIRO)
Translational Metabolic Oncology (IDC-TMO)
POF Topic(s) 30203 - Molecular Targets and Therapies
Forschungsfeld(er) Immune Response and Infection
Radiation Sciences
PSP-Element(e) G-502700-003
G-501000-001
DOI 10.1016/j.jhepr.2021.100354
Scopus ID 85122807390
PubMed ID 34704004
Erfassungsdatum 2021-12-16
[➜Korrektur melden]